Patents by Inventor Harvey R. Kaslow

Harvey R. Kaslow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
    Patent number: 7341733
    Abstract: Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e.g., pertussis toxin but directed against another target antigen (e.g., a cancer-related antigen) in a mammalian patient.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: March 11, 2008
    Inventor: Harvey R. Kaslow
  • Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
    Publication number: 20030113311
    Abstract: Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e.g., pertussis toxin but directed against another target antigen (e.g., a cancer-related antigen) in a mammalian patient.
    Type: Application
    Filed: December 6, 2002
    Publication date: June 19, 2003
    Inventor: Harvey R. Kaslow
  • Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
    Patent number: 6514499
    Abstract: Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e.g., pertussis toxin but directed against another target antigen (e.g., a cancer-related antigen) in a mammalian patient.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: February 4, 2003
    Inventor: Harvey R. Kaslow
  • Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
    Patent number: 6056960
    Abstract: Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e.g., pertussis toxin but directed against another target antigen (e.g., a cancer-related antigen) in a mammalian patient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 2, 2000
    Inventor: Harvey R. Kaslow
  • Mutagenized DNA molecules encoding modified subunit a of Cholera-toxin
    Patent number: 5874287
    Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: February 23, 1999
    Assignee: Amgen Inc.
    Inventors: W. Neal Burnette, Harvey R. Kaslow
  • Modified cholera toxin based on mutagenized subunit A
    Patent number: 5770203
    Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: June 23, 1998
    Assignees: Amgen Inc., University of Southern California
    Inventors: W. Neal Burnette, Harvey R. Kaslow
  • Composition with modified pertussis toxin
    Patent number: 5165927
    Abstract: A modified pertussis toxin suitable as a pertussis vaccine having an essentially unmodified B-oligomer and a catalytic subunit which is inactivated by treatment with polyphosphate compounds, sulfhydryl reductants and mild detergents followed by modification of the activated --SH groups to inhibit ADP-ribosylating activity.
    Type: Grant
    Filed: April 9, 1991
    Date of Patent: November 24, 1992
    Assignee: University of Southern California
    Inventor: Harvey R. Kaslow
  • Selective modification of the catalytic subunit of pertussis toxin
    Patent number: 5032398
    Abstract: A modified pertussis toxin suitable as a pertussis vaccine having an essentially unmodified B-oligomer and a catalytic subunit which is inactivated by treatment with polyphosphate compounds, sulfhydryl reductants and mild detergents followed by modification of the activated --SH groups to inhibit ADP-ribosylating activity.
    Type: Grant
    Filed: August 1, 1986
    Date of Patent: July 16, 1991
    Inventor: Harvey R. Kaslow